Abstract
Positron emission tomography/computed tomography (PET/CT) is one of the key imaging techniques in oncology. Hybrid PET/CT provides both structural and metabolic information and in general improves sensitivity, specificity, and reporter confidence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811–7.
Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18F-FDG PET scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–14.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18F-fluoro-2-deoxyglucose and carbon-11-methionine. Eur J Nucl Med. 1999;26:1363–78.
Culverwell AD, Scarsbrook AF, Chowdhury FU. False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. Clin Radiol. 2011;66:366–82.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.
Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumour imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.
Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.
Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.
Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;2(354):496–507.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ballinger, J., Gnanasegaran, G. (2016). 18F-FDG and Non-FDG PET Radiopharmaceuticals. In: Szyszko, T. (eds) PET/CT in Oesophageal and Gastric Cancer. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-29240-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-29240-3_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29238-0
Online ISBN: 978-3-319-29240-3
eBook Packages: MedicineMedicine (R0)